MAP17 is a small, 17-kDa, non-glycosylated membrane protein that is overexpressed in a percentage of carcinomas. In the present work, we have analyzed the role of MAP17 expression during mammary cancer progression. We have found that MAP17 is expressed in 60% human mammary tumors while it is not expressed in normal or benign neoplasias. MAP17 levels increased with breast tumor stage and were strongly correlated with mammary tumoral progression. A significant increase in the levels of reactive oxygen species (ROS) was observed in MAP17-expressing cells, as compared with parental cells. This increase was further paralleled by an increase in the tumorigenic capacity of carcinoma cells but not in immortal non-tumoral breast epithelial cells, which provides a selective advantage once tumorigenesis has begun. Expression of specific MAP17 shRNA in proteinexpressing tumor cells reduced their tumorigenic capabilities, which suggests that this effect is dependent upon MAP17 protein expression. Our data show that ROS functions as a second messenger that enhances tumoral properties, which are inhibited in non-tumoral cells. We have found that p38a activation mediates this response. MAP17 triggers a ROS-dependent, senescence-like response that is abolished in the absence of p38a activation. Furthermore, in human breast tumors, MAP17 activation is correlated with a lack of phosphorylation of p38a. Therefore, MAP17 is overexpressed in late-stage breast tumors, in which oncogenic activity relies on p38 insensitivity to induce intracellular ROS.
MAP17 is a small, 17-kDa, non-glycosylated membrane protein that is overexpressed in a percentage of carcinomas. In the present work, we have analyzed the role of MAP17 expression during mammary cancer progression. We have found that MAP17 is expressed in 60% human mammary tumors while it is not expressed in normal or benign neoplasias. MAP17 levels increased with breast tumor stage and were strongly correlated with mammary tumoral progression. A significant increase in the levels of reactive oxygen species (ROS) was observed in MAP17-expressing cells, as compared with parental cells. This increase was further paralleled by an increase in the tumorigenic capacity of carcinoma cells but not in immortal non-tumoral breast epithelial cells, which provides a selective advantage once tumorigenesis has begun. Expression of specific MAP17 shRNA in proteinexpressing tumor cells reduced their tumorigenic capabilities, which suggests that this effect is dependent upon MAP17 protein expression. Our data show that ROS functions as a second messenger that enhances tumoral properties, which are inhibited in non-tumoral cells. We have found that p38a activation mediates this response. MAP17 triggers a ROS-dependent, senescence-likeIntroduction A genome-wide retroviral cDNA screen was conducted to find genes that confer a selective advantage upon cancer cells once tumorigenesis has begun. This screen has allowed us to identify MAP17 (Guijarro et al., 2007a) , a small, non-glycosylated membrane-associated protein of 17 kDa, which is located on the plasma membrane and the Golgi apparatus (Kocher et al., 1995 (Kocher et al., , 1996 . The protein sequence possesses a hydrophobic amino-terminus containing 13 amino acids that encodes a PDZ-binding domain and two transmembrane regions (Jaeger et al., 2000; Lanaspa et al., 2007) . MAP17 was first described using differential display overexpression in carcinomas (Kocher et al., 1995 (Kocher et al., , 1996 . MAP17 binds several PDZ domain-containing proteins, including PDZK1, NHERF proteins, NaPiIIa and NHe3. Together with NHRF3 and NHRF4, overexpression of MAP17 in opossum kidney cells leads to internalization of NaPilla to the trans-Golgi network (Pribanic et al., 2003; Lanaspa et al., 2007) . The physiological role of MAP17 in proximal tubules is not known, but it stimulates specific Na-dependent transport of mannose and glucose in Xenopus oocytes (Blasco et al., 2003) and mammary cells (Guijarro et al., 2007a) .
Using a melanoma cell model system, we have previously shown that MAP17 enhances tumorigenic properties of melanoma cells through an increase in reactive oxygen species (ROS; Guijarro et al., 2007b) . At the molecular level, we have found that MAP17 protects Rat1a fibroblasts from Myc-induced apoptosis through ROS-mediated activation of the PI3K/AKT signaling pathway (Guijarro et al., 2007d) . In MAP17-overexpressing cells, we showed that a fraction of PTEN undergoes oxidation. Furthermore, activation of AKT by MAP17, as measured by Thr308 phosphorylation, was independent of PI3K activity. Notably, modulation of ROS by antioxidant treatment prevented activation of AKT and restored the level of apoptosis in serumstarved Rat1/c-Myc fibroblasts (Guijarro et al., 2007d) .
MAP17 is overexpressed in a great variety of human carcinomas (Guijarro et al., 2007c) . In prostatic and ovarian carcinomas, immunohistochemical analysis of MAP17 during cancer progression shows that its over-expression strongly correlates with tumoral progression (Guijarro et al., 2007d) . More than 80% of human cancers are carcinomas, and the pattern of expression of MAP17 may be important for understanding the behavior of these tumors (Guijarro et al., 2007c) . Therefore, it is important to determine how MAP17 deregulates carcinoma cell growth.
In the present work, we describe the increase of MAP17 protein levels in a subset of human mammary carcinomas and how MAP17 levels correlated with the progression of human breast tumors. MAP17 enhanced cell proliferation decreasing doubling time, increases foci formation and growth in soft agar. This increase in the tumorigenic capacities occurs when MAP17 is ectopically expressed in human breast carcinoma cells but not in immortal non-tumoral breast epithelial cells. Moreover, this effect was dependent on the activation of p38a. These results suggest that MAP17 provides a selective advantage once tumorigenesis has begun.
Results
MAP17 overexpression in human mammary tumors correlates with advanced stages MAP17 is overexpressed in carcinomas, specifically in ovarian and prostate carcinomas, in which its overexpression is correlated with advanced stages (Guijarro et al., 2007c) . Therefore, we first wanted to confirm whether MAP17 expression is a marker for human breast tumors. To assess the overexpression of MAP17 protein, we immunohistochemically analyzed 50 samples from mammary tumors at different stages, including non-tumoral tissues and intraductal neoplasias; Figure 1 ). To homogenize the results, we generated a tissue array using all the samples. The array was labeled with antiMAP17 antibodies, and the MAP17 levels were independently evaluated (Guijarro et al., 2007d) . The analysis of the samples showed that MAP17 expression positively correlated with the tumor stage (Figure 1 ). Both normal mammary ductal and intraductal neoplasias cells showed no staining for MAP17, which indicates low levels of this protein (Figure 1 ). MAP17 expression was detected mainly in carcinomas at stage T2 or T3s (Figure 1 ; Chi square test, Po0.0001).
MAP17 confers a proliferative advantage to breast carcinoma cells but not to non-tumoral immortal epithelial cells MAP17 was overexpressed in human mammary carcinomas, and expression was correlated with increased malignancy and tumor grade. Therefore, we next investigated the role of MAP17 in mammary tumorigenesis. To study the biological effect of MAP17 in mammary epithelial cells, we selected cells that do not express MAP17 mRNA. We ectopically expressed the wild-type human MAP17 cDNA and studied the alterations in the biological properties of these cells. We choose human mammary epithelial cells (HMECs), which are non-tumoral, pre-senescent cells from normal mammary epithelium, and T47D, a tumorigenic mammary carcinoma established cell line. 
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As HMECs are normal epithelial cells with a limited replicative lifespan (Stampfer and Yaswen, 2000; Dimri et al., 2005; Lewis et al., 2006) , we first generated an immortal population by expressing the catalytic subunit of telomerase, hTERT (Herbert et al., 2002; Stampfer and Yaswen, 2003; Dimri et al., 2005) . We verified the immortality of the population by maintaining it beyond passage 60 (normal cells enter senescence at approximately passage 10). Immortal HMECs expressing hTERT (HMEC-Ts) were infected with a retrovirus carrying MAP17 cDNA driven by an LTR promoter (Figure 2a ). MAP17-expressing cultures grew more slow than parental cells. The doubling time of the MAP17-expressing cultures increased and they ended in arrested state (Figure 2b ). We observed that most MAP17-expressing HMEC-Ts stopped growth and changed morphology into a senescence-like state; however, some apoptosis was also observed in the culture (usually less than 10% of cells). These senescent cells also stained for senescence-associated b-gal (Figure 2c ). Our results indicate that MAP17 expression does not induce transforming capabilities in HMEC-Ts.
Because MAP17 is detected only in late-stage breast tumors (Figure 1 ), we decided to study the role of MAP17 expression in established breast cells that were already tumoral. T47D do not express MAP17 (Guijarro et al., 2007c) , probably originated from a non-MAP17 expressing tumor. We therefore generated MAP17-expressing T47D cells as before and maintained the subcultivation for short times to avoid culture drift.
We selected several mass cultures and characterized the MAP17 mRNA expression by RT-PCR ( Figure 2c 
Downregulation of MAP17 decreases the malignant behavior of tumor cells
We have shown that ectopic MAP17 expression increases the tumorigenicity of breast tumor cells. However, it is possible that this result is an indirect effect due to permanent alterations caused by MAP17. To explore this possibility, we studied the prevalence of MAP17-induced properties on further downregulation of MAP17. We expressed specific MAP17 shRNAs in MAP17-expressing T47D cells. We performed the experiments in all MAP17-expressing mass cultures from Figure 2c and obtained results identical to those results shown in Figure 3 . In the later figure, we show results from mass cultures expressing MAP17 shRNA derived from MAP17 expressing clone B. The resultant MAP17 shRNA-expressing clones have lost MAP17 expression (Figure 3a) , and this change led to a decrease in colony size and in the number of colonies in both clonability and the soft agar assay (Figures 3b and c) . These data indicate that continuous MAP17 expression is required to maintain the increase in oncogenic capabilities.
Next, we analyzed the effect of downregulating endogenous MAP17. We have previously shown that the mammary carcinoma cell line MDA-MB-431 expresses high levels of MAP17 mRNA (Guijarro et al., 2007d) . Again, MAP17 shRNA reduced the levels of protein, as compared with vector-expressing cells ( Figure 3d ). The reduction in the levels of MAP17 is accompanied by a decrease in the proliferation ratio ( Figure 3e ) and the ability to form colonies at low density ( Figure 3f ). Moreover, a reduction in MAP17 levels decreased the number and size of colonies growing in soft agar (Figures 3g and h ).
The enhanced oncogenic capabilities induced by MAP17 in tumoral cells correlated to an increase of intracellular ROS Growing evidence suggests that ROS function as secondary messengers in intracellular signaling cascades that induce and maintain the oncogenic phenotype of tumoral cells. ROS have been shown to induce proliferation, survival and cellular migration (Martindale and Holbrook, 2002; Behrend et al., 2003; Pelicano et al., 2004) . We have observed that MAP17 can induce ROS production in Rat1A cells (Guijarro et al., 2007d) . Therefore, we investigated whether MAP17 expression induces an increase of intracellular ROS in carcinoma cells and whether this increase was responsible for their tumorigenic capabilities. First, we measured the level of ROS in living cells with the fluorescent probe DCF. MAP17-expressing clones showed higher levels of ROS with respect to their parental counterparts (Figure 4a ), which can be inhibited by ROS scavengers (Supplementary Figure  2) ; We also found that ROS increased in HMEC-Ts expressing MAP17 (Figure 4a ). And Ros scavengers reduced the senescent phenotype observed in HMEC-T expressing MAP17 (Supplementary Figure 3) . ROS was abolished by MAP17shRNA in T47D-expressing MAP17 cells, indicating that the effect observed in the clones is due to MAP17 expression (Figure 4a ). Finally, we determined that the expression of shRNA against MAP17 in MDA-MB-431 cells also reduced ROS levels in these cells (Figure 4b) .
As ROS can function as a secondary messenger (Irani et al., 1997) , we next checked whether some of the transforming properties of MAP17 were linked to the increased intracellular ROS level. Thus, we examined clonability and growth in soft agar in the presence of antioxidants, such as GSH. We found that the presence of antioxidants reduced the oncogenic properties of the MAP17-expressing cells; they had reduced colony- (Figure 4c ). The same effect was found in the soft agar growth assay; antioxidants reduced the number and size of colonies of MAP17-expressing cells (Figures 4d-f) . Notably, the colony formation efficiency and colony size were similar to untreated parental cells.
Our data indicated that the expression of MAP17 in established human breast cancer cells induces an increase in intracellular ROS levels that has an important role in the enhancement of the malignant cell behavior. However, in non-tumoral cells, ROS may have the opposite effect (that is, inducing cellular senescence). MAP17 increases tumor properties of breast carcinoma cells MV Guijarro et al p38a activation limits MAP17 contribution to progression in breast tumors Recently, it has been reported that p38a is a sensor for ROS levels and functions as a switch between its oncogenic and suppressive actions (Dolado et al., 2007) . Inactivation of p38a may be necessary for ROS, and hence MAP17, to enhance tumorigenic properties of the cells. To explore this hypothesis, we first studied the effect of MAP17 expression on p38a phosphorylation at T180/Y182. Ectopic expression of MAP17 induced p38a phosphorylation in HMEC-Ts but not in T47D cells (Figure 5a ). Next, we downregulated p38a in HMEC-Ts by expressing p38a shRNA (Figure 5b) . In these cells, we expressed MAP17 and observed that p38a phosphorylation was not detected (Figure 5c ). In the p38a shRNA-expressing cells, MAP17-induced senescence was greatly reduced (Figures 5d and e) . HMEC-Ts expressing MAP17 in the absence of p38a then grew faster and formed more colonies when seeded at low density (Figures 5f and g ). These results confirm the importance of p38a in mediating the MAP17 effect. Finally, if p38a limits MAP17-induced enhancement of tumoral properties, we should find a correlation in fresh tumor samples. To investigate this hypothesis, we stained the mammary tumor samples for p38a phosphorylation at T180/Y182. We also stained the samples for AKT phosphorylation at S473 because we have previously shown a functional correlation between MAP17 and AKT activation (Guijarro et al., 2007d) . Our analysis showed a statistically significant correlation between MAP17 expression and AKT phosphorylation ( Figure 6 ). We also found a significant correlation between MAP17 expression and a lack of p38a phosphorylation ( Figure 6 ). Furthermore, tumors not expressing MAP17 showed low levels of AKTS473 and high levels of p38 phosphorylation ( Figure 6 ).
All these data reinforces the functional relationship between MAP17 and p38a phosphorylation.
Discussion
MAP17 protein is overexpressed in malignant tumors (stages II and II) but not in normal, benign or early stage human breast tumors. Therefore, MAP17 can be considered an independent marker of malignancy in human breast tumors. We have previously shown that MAP17 overexpression correlates with malignant stages of ovarian and prostate tumors (Guijarro et al., 2007c) . The relevance of MAP17 as a general marker for the malignant stages of human tumors still needs to be confirmed in other tumors and larger cohorts. However, all tissues explored thus far have shown similar patterns of MAP17 expression. Furthermore, MAP17 expression seems to correlate with AKT473 phosphorylation and a p38T180/Y182 dephosphorylated stage. These expression patterns provide a mechanistic insight (p38 desensitization) and a possible target for future therapies (AKT inhibition).
Carcinoma cells, but not non-tumoral epithelial cells, which stably express MAP17, show an increased tumoral phenotype. This phenotypic change included enhanced proliferative capabilities in both the presence and the absence of cell contact. The increased tumorigenic properties induced by MAP17 are associated with an increase in ROS. This increase is because MAP17 increases endogenous ROS, and the antioxidant treatment of MAP17-expressing cells entails a reduction in the tumorigenic properties of these cells. Thus, ROS generated in a MAP17-dependent manner function as intracellular signals and induce a growth-related program. Accumulating evidence implicates ROS in signaling cascades related to cell proliferation and transformation (Fernandez-Pol et al., 1982; Church et al., 1993; Sundaresan et al., 1995; Burdon, 1996; Yan et al., 1996; Irani et al., 1997; Bae et al., 1999; Arnold et al., 2001) .
Oxidative stress has been considered to be a byproduct of cellular metabolism. However, ROS may be involved in the regulation of signal transduction pathways (Hancock et al., 2001; Yoon et al., 2002; Apel and Hirt, 2004) . ROS can also cooperate with other oncogenic signals in cellular transformation and cancer (Suh et al., 1999; Woo and Poon, 2004) . The protumoral effects by ROS, including gene expression regulation (Allen and Tresini, 2000) , increased mutagenic rates (Irani et al., 1997) and genomic instability (Woo and Poon, 2004 ) may occur at different levels. High levels of ROS have been detected in cancer cell lines and tumors from different tissues (Fernandez-Pol et al., 1982; Szatrowski and Nathan, 1991; Toyokuni et al., 1995) , supporting the causal link between oxidative stress and cancer (Ames, 1983; Wagner and Nebreda, 2009; Cuadrado and Nebreda, 2010) . ROS increases are sensed by p38a, and activation of p38 a limits the oncogenic capability of MAP17 by driving these cells to senescence or apoptosis. This senescence induction may explain why MAP17 does not induce tumorigenic transformation in immortal nontumoral cells. In these cells, ROS are probably sensed as pernicious stress rather than as second messengers. The reduction in proliferative capabilities observed in HMEC-Ts supports this hypothesis. Downregulation of p38a prevents the cells from responding to MAP17-induced stress. Therefore, p38a is a sensor of ROS and functions as a switch between ROS pro-oncogenic and tumor-suppressive capabilities (Wagner and Nebreda, 2009; Cuadrado and Nebreda, 2010) . Furthermore, the inactivation of the p38a response is necessary for ROS, and hence MAP17, to enhance the tumorigenic capabilities of cells. Therefore, cells with impaired p38a response to ROS are more susceptible of being oncogenically altered by MAP17 (see also Supplementary Figure 4) .
In addition to its role in coordinating the stress response, p38a also regulates other cellular processes in a cell-type specific manner (Adams et al., 2000; Nebreda and Porras, 2000) . p38a negatively regulates the malignant transformation induced by oncogenic Ras, even in the absence of functional p53 response (Dolado et al., 2007) . Different mechanisms have been proposed to explain this tumor suppressive role, including the (M17) were grown in the presence of 10% FBS. At 90% confluence the cells were harvested and protein extracted. Total protein was resolved using PAGE, and p38a phosphorylated at T180/Y182 (p38a P ), or p38a total protein (p38a) examined using western blot. The experiment was performed more than three independent times, with similar results. (b) p38 shRNA reduces p38 levels. HMEC-T cells expressing empty vector (V) or p38a shRNA (sh) were grown in the presence of 10% FBS. At 90% confluence the cells were harvested and protein extracted. Total protein was resolved using PAGE, and tubulin or p38a total protein (p38a) examined using western blot. The experiment was performed more than three independent times, with similar results. (c) Downregulation of p38a inhibits its MAP17-induced phosphorylation. T47D cells expressing MAP17 cDNA (see a) were transfected with empty vector (V) or p38a sh. After selection, cells were grown in the presence of 10% FBS. At 90% confluence the cells were harvested and protein extracted. Total protein was resolved using PAGE, and tubulin or p38a total protein (p38a) examined using western blot. Parental T47D cells not expressing MAP17 are shown as control (c). The experiment was performed more than three independent times, with similar results. (d) Expression of MAP17 mRNA in different cultures expressing p38shRNA. HMEC-T cells expressing p38a shRNA (see b) were transfected with MAP17 cDNA. After selection several mass cultures were selected and grown. Three of these clones were selected for further experiments (mass cultures 1, 2 and 3). activation of p53-dependent cell cycle arrest (Bulavin et al., 2002) , induction of premature senescence (Wang et al., 2002) and upregulation of cell cycle inhibitors, such as p16 and p21 (Bulavin and Fornace, 2004) (Nicke et al., 2005) . However, p38a is not a general inhibitor of oncogenic transformation; it specifically modulates malignant transformations induced by oncogenes that produce ROS (Dolado et al., 2007) . Notably, some human cancer cells can bypass the inhibitory role of p38a on ROS accumulation, and this leads to enhanced tumorigenicity. Thus, oxidative stress detected by p38a is an important mechanism that negatively regulates the onset of cancer. Therefore, p38a limits MAP17-induced enhancement of tumoral properties in mammary tumor cells.
The signaling pathways that lead to the activation of p38 involve several upstream kinases, including ASK1 (MAP3K5), which has a major role in p38a activation by oxidative stress (Tobiume et al., 2001 ). ASK1 activation may involve oligomerization and autophosphorylation. In unstressed cells, this activation is prevented by the binding of proteins, such as thioredoxin and Gstm1, which are sensitive to stress and dissociate from ASK1 after oxidative stress and heat shock, respectively (Dorion et al., 2002; Matsukawa et al., 2004) .
MAP17-induced ROS may oxidize certain cysteine residues of thioredoxin and induce its dissociation from ASK1. This action would induce the activation of the JNK and p38 pathways. MAP17 oncogenic abilities would only be reflected in cell lines that have acquired the ability to uncouple p38a activation from oxidative stress production, resulting in enhanced tumorigenicity. In many cases, this mechanism relies on the ability of the GST family members Gstm1 and Gstm2 to impair p38a activation in response to ROS accumulation (Dorion et al., 2002) .
ROS can also directly modify signaling proteins through modifications such as nitrosylation, carbonyla- tion, disulfide bond formation and glutathionylation (England and Cotter, 2005) . A direct effect has been shown on the protein tyrosine phosphatase-1B, which is inhibited by oxidation of a thiol in the active site (Lee et al., 1998; Barrett et al., 1999) , leading to increased phosphotyrosines on many cell proteins. We have also previously shown that MAP17-induced ROS activate the PI3K pathway. This activation likely occurs through direct oxidation and inactivation of PTEN and other AKT phosphatases, and AKT activation is maintained, even in the absence of PI3K signal (Guijarro et al., 2007d) . AKT pathway activation induced by MAP17 expression may explain some of the properties described here. Under certain conditions, an increase in AKT activity may lead to a decrease in p38 phosphorylation; a decrease in AKT may lead to an increase in p38a phosphorylation, possibly through the release of the activity of p38 upstream kinases (most likely ASK1 and MEKK3) (Samanta et al., 2009 ). This relationship is further supported by the strong direct correlation between MAP17 levels and AKT phosphorylation and by the p38a dephosphorylation in breast tumors found in this work ( Figure 6 ) and by others (Huang et al., 2003) . Furthermore, AKT activation may be involved in promoting survival of cells defective for p38 (Zuluaga et al., 2007) and in the increase of tumorigenic properties (Carnero, 2010) . However, we suggest that other pathways induced by MAP17 could coexist at the transcriptional level, as has been described in other systems (Klaunig et al., 1998; Droge, 2002) . In summary, MAP17 is a biomarker of malignant stages of breast tumors, in which it can enhance tumorigenic properties through ROS. Moreover, p38a limits the contribution of MAP17 in advancing the malignant state of breast tumors.
Materials and methods
Cell culture T47D mammary carcinoma cells were obtained from ATCC and maintained in Dulbecco's modified Eagle's medium (DMEM) with glutamax (Gibco, Alcobendas, Madrid, Spain) containing 10% fetal bovine serum (FBS, Sigma, Tres Cantos, Madrid, Spain), penicillin, streptomycin and fungizone. Cultures were selected when indicated with 75 mg/ml hygromycin (Calbiochem, Barcelona, Spain), 400 mg/ml G418 (Sigma) or 2 mg/ml puromycin (Fluka, Tres Cantos, Madrid, Spain). Human MAP17 full cDNA was cloned in pBabepuro or pWZLhygro, and expressing cultures were generated by retroviral infection. Six mass cultures were selected and tested; all behaved similarly. For this work, 3 representative mass cultures were used in each case. HMECs (Invitrogen, Barcelona, Spain) were infected with retrovirus carrying pBabepuro hTERT (HMEC-Ts), or pBabepuro alone (parental, P). Cells were selected with 2 mg/ml puromycin, and the mass culture was grown for 20 passages (around 40 doublings) before any other experiments were initiated. Primary and immortal HMEC-Ts were cultured using standard procedures in HMEC medium (Invitrogen) supplemented with 10% FBS and antibiotics.
Retroviral-mediated gene transfer
Infections were performed as previously indicated by (Carnero et al., 2000) . Packaging LinXE cells were plated in a 10-cm dish, incubated for 24 h and then transfected by calcium phosphate precipitation with 20 mg of the retroviral plasmid (16 h at 37 1C). After 48 h, the virus-containing medium was filtered (0.45-mm filter, Millipore, Madrid, Spain) and supplemented with 8 mg/ml polybrene (Sigma) and an equal volume of fresh medium. Target cells were seeded at 10 6 cells per 10-cm dish and incubated overnight. For infections, the culture medium was replaced by the appropriate viral supernatant; the culture plates were centrifuged (1 h, 1500 r.p.m.) and incubated at 37 1C for 16 h. The infected cell population was purified using the appropriate selection.
RT-PCR Total RNA was purified using TRI-REAGENT (Molecular Research Center, Cincinnati, OH, USA). Reverse transcription was performed with 5 mg of mRNA using MMLV reverse transcriptase (Promega, Alcobendas, Madrid, Spain) and oligodT primer, according to the manufacturer's recommendations. The following primers were used to amplify specific cDNA regions: MAP17 forward 5 Surrogate assays Growth in low serum. A time-course curve of parental and MAP17-expressing cells was generated by seeding 10 4 cells in 2.5-cm dishes in triplicate. After 24 h, the medium was changed (day 0), and the indicated culture medium was added. After 4 days, the cells were fixed and stained with crystal violet. After extensive washing, crystal violet was resolubilized in 15% acetic acid and quantified at 595 nm as a relative measure of cell number. Values are expressed as the percentage of cell growth of cells growing in the presence of 10% FBS. Zero percent refers to the number of cells at day 0. Culture media tested were: NS (no serum or complements used, cells were grown in DMEM alone), 0.5% (DMEM þ 0.5% FBS), 0.5% þ ITS (DMEM þ 0.5% FBS þ insulin, transferrin and selenium) and ITS (DMEM þ insulin, transferrin and selenium).
Proliferation curve. A total of 10 4 cells were seeded in 2.5-cm plates. The medium was replaced every three days. At the indicated times, the cells were fixed, stained with crystal violet and thoroughly washed.
Clonability. In 10-cm plates, the following quantities of cells were seeded: 10 2 , 5 Â 10 2 , 10 3 or 10 4 . The medium was replaced every three days, and after 10 days, the cells were fixed and stained with crystal violet. After extensive washing, the colonies were counted. Values are expressed as the percentage of colonies related to the parental cell line.
Growth in soft agar. To measure the anchorage-independent growth, 2 Â 10 4 cells were suspended in 1.4% agarose D-1 Low EEO (Pronadisa, Alcobendas, Madrid, Spain) growth medium containing 10% FBS, disposed onto a solidified base of growth medium containing 2.8% agar and overlaid with 1 ml of growth medium. After 24 h, medium containing 10% FBS was added to each 35-mm dish and replaced twice weekly. Colonies were scored after 3 weeks, and all values were measured in triplicate. Photographs were taken with a phase-contrast microscope (Olympus).
SA b-gal activity Senescence-associated (SA) b-galactosidase (b-gal) activity was measured as previously described (Carnero and Beach, 2004; Ruiz et al., 2008) , except that cells were incubated in 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (XGal) at pH 5.5 to increase the sensitivity of the assay. The percentage of cells expressing SA b-gal was quantified by visual analysis of 4400 cells per 10-cm plate in triplicate.
Immunodetection of MAP17
Cells were trypsinized and cytospinned onto glass coverslips. The following day cells were fixed with acetone for 10 min and then incubated with MAP17 monoclonal antibody for 30 min. Cells were washed three times with PBS and incubated for additional 30 min with a secondary goat anti-mouse antibody (DAKO Cytomation; Glostrup, Denmark) diluted 1:50 in FBS. After washing, slides were mounted with Aquatex (Merck, Barcelona, Spain). Photos were taken in an Olympus Provis Microscope AX70.
ROS fluorescent detection
To visualize intracellular ROS levels, cells grown on coverslips were washed twice with warm PBS. The cells were then incubated at 37 1C with 8 mM of CM-H 2 DCFDA in warm PBS supplemented with 2.5 mM glucose for 15 min. The PBS was then replaced with DMEM supplemented with 10% FBS, and cells were incubated for an additional 10 min under the same conditions. Cells were washed once again with warm PBS and fixed with 4% paraformaldehyde (Sigma) at room temperature for 5 min. The fixed cells were washed three times with PBS, and the coverslips were mounted in Mowiol (Sigma). Intracellular ROS levels were visualized using a confocal ultra-spectral microscope Leica TCS-SP2-AOBS-UV (Leica, Barcelona, Spain).
Tissue microarray immunohistochemistry
To corroborate the in vitro results, immunohistochemical studies were performed in mammary tumor specimens included in a TMA (tissue microarray). This TMA was constructed using standard methods, which employed paraffin-embedded tumoral samples kindly provided by the Pathology Department at Hospital Vall d'Hebron. Three-micrometer slices were sectioned from the TMA block and applied to special immunochemistry coated slides (DAKO). The slides were baked overnight in a 56 1C oven, deparaffinized in xylene for 20 min, rehydrated through a graded ethanol series and washed with PBS. A heatinduced epitope retrieval step was performed by heating a slide in a solution of sodium citrate buffer pH 6.5 for 2 min in a conventional pressure cooker. After heating, the slide was incubated with proteinase K for 10 min and then rinsed in cool running water for 5 min. Endogenous peroxide activity was quenched with 1.5% hydrogen peroxide (DAKO) in methanol for 10 min, and incubation with the primary antibody antiMAP17 (1:250) was performed (40 min). After incubation, immunodetection was carried out with the EnVision (DAKO) visualization system using diaminobenzidine chromogen as the substrate, according to the manufacturer's instructions. Immunostaining was performed in a TechMate 500 automatic immunostaining device (DAKO).
Antibodies phospho-p38 MAPK (Thr180/Tyr182) (12F8) rabbit mAb #4631 for IHCh (Cell Signaling, Barcelona, Spain); phosphop38 MAPK (Thr180/Tyr182) (3D7) rabbit mAb for WB (Cell Signaling); phospho-AKT (S473); monoclonal MAP17 antibody, which was generated from bacterial-purified GST-MAP17 protein. Several clonal antibodies were tested for specificity and validated by antigen competition for full characterization).
